STUDIES ON CLINICAL EFFECT AND EXCRETION INTO WOUND EXUDATE OF CEFROXADINE IN SURGERY

DOI Web Site PubMed

Bibliographic Information

Other Title
  • 軟部組織感染症に対するCefroxadineの臨床的並びに創滲出液移行性の検討
  • ナンブ ソシキ カンセンショウ ニ タイスル Cefroxadine ノ リン

Search this article

Abstract

Clinical effect and excretion into wound exudate of a new semisynthetic cephalosporin cefroxadine (CXD), were studied.<BR>CXD was given in 25 cases of surgical infections; 6 cases of wound infection, 9 cases of abscess, 9 cases of infected atheroma and 1 case of furuncle. CXD was orally administered in daily dose of 750 to 1,500mg.<BR>Clinical results were excellent in 1 case, good in 18 cases, fair in 3 cases and poor in 3 cases. The overall clinical efficacy rate was 76.0%.<BR>Clinical efficacy classified by diagnosis was 66.7% in wound infection, 66.7% in abscess, 88.9% in infected atheroma, and 100% in furuncle. Side effects were not observed in all cases among 25 patients in CXD trials.<BR>Studies of excretion into wound exudate of CXD were performed in 1 postoperative case of mamma carcinoma after oral administration of 500mg of CXD. The concentration of CXD in exudate was 1.12μg/ml in 2 hours, 3.48μg/ml in 3 hours, 4.13μg/ml in 4 hours, 5.56μg/ml in 5 hours and 4.41μg/ml in 6 hours after administration, which was observed that CXD was excreted in wound exudate in high concentration.

Journal

Details 詳細情報について

Report a problem

Back to top